BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35837383)

  • 1. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.
    Zhang X; Min S; Yang Y; Ding D; Li Q; Liu S; Tao T; Zhang M; Li B; Zhao S; Ge R; Yang F; Li Y; He X; Ma X; Wang L; Wu T; Wang T; Wang G
    Front Immunol; 2022; 13():876355. PubMed ID: 35837383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma.
    Song X; Chen Q; Wang J; Mao Q; Xia W; Xu L; Jiang F; Dong G
    J Cell Mol Med; 2022 Jan; 26(2):436-448. PubMed ID: 34877770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
    Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
    BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing an 8-gene immune prognostic model based on TP53 status for lung adenocarcinoma.
    Wu G; Wang Y; Wan Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24538. PubMed ID: 35689561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.
    Liu H; Xin T; Duan H; Wang Y; Shao C; Zhu Y; Wang J; He J
    Aging (Albany NY); 2023 Jun; 15(12):5650-5661. PubMed ID: 37341998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
    Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
    BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
    Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
    Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
    Li H; Lu H; Cui W; Huang Y; Jin X
    Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.
    Zhou B; Gao S
    Cancer Immunol Immunother; 2022 May; 71(5):1183-1197. PubMed ID: 34635925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma.
    Xu JZ; Gong C; Xie ZF; Zhao H
    Front Oncol; 2020; 10():593022. PubMed ID: 33585210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
    Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
    EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-SaccĂ  M
    J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.
    He A; Zhang R; Wang J; Huang Z; Liao W; Li Y; Wang C; Yang J; Feng Q; Wu L
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e129-e140. PubMed ID: 33852776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
    Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
    Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.